AIP
LYEL icon

Ameritas Investment Partners’s Lyell Immunopharma LYEL Stock Holding History

Ameritas Investment Partners’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-856
Closed -$9.21K – 3281
2025
Q1 		$9.21K Hold
856
– – ﹤0.01% 2848
2024
Q4 		$11K Hold
856
– – ﹤0.01% 2877
2024
Q3 		$23.6K Hold
856
– – ﹤0.01% 2563
2024
Q2 		$24.8K Hold
856
– – ﹤0.01% 2525
2024
Q1 		$38.2K Hold
856
– – ﹤0.01% 2289
2023
Q4 		$33.2K Hold
856
– – ﹤0.01% 2358
2023
Q3 		$25.2K Buy
856
+207
+32% +$9.83K ﹤0.01% 2434
2023
Q2 		$41.3K Hold
649
– – ﹤0.01% 2157
2023
Q1 		$30.6K Hold
649
– – ﹤0.01% 2253
2022
Q4 		$38.7K Hold
649
– – ﹤0.01% 2234
2022
Q3 		$95K Hold
649
– – ﹤0.01% 1524
2022
Q2 		$84K Buy
649
+74
+13% +$7.56K ﹤0.01% 1639
2022
Q1 		$58K Buy
575
+484
+532% +$58.6K ﹤0.01% 1975
2021
Q4 		$14K Hold
91
– – ﹤0.01% 2789
2021
Q3 		$27K Buy
+91
New +$27.3K ﹤0.01% 2535

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameritas Investment Partners's LYEL Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 856 shares — an estimated $9.21K sold.

Ameritas Investment Partners first reported a position in LYEL in Q3 2021 and held it in 15 quarters. The position peaked at $95K in Q3 2022. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 856 Lyell Immunopharma shares in Q2 2025, an estimated $9.21K.
  • Ameritas Investment Partners first reported a position in Lyell Immunopharma in Q3 2021 and held it in 15 quarters.
  • Ameritas Investment Partners's Lyell Immunopharma position peaked at $95K in Q3 2022.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.